Teva Ends Collaboration, Returns Clinic-Bound GPCR Candidate to Sosei

Teva Pharmaceutical Industries has ended a 2.5-year, up-to-$410 million-plus collaboration with Sosei Group’s Heptares Therapeutics subsidiary to develop and commercialize Heptares’ lead candidate HTL0022562 and other novel small-molecule calcitonin gene-related peptide (CGRP) antagonists for migraine and other severe headaches, Sosei said today.Sosei said Teva’s termination of the companies’ licensing and drug discovery agreement reflected Teva’s restructuring anno